The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders —a double-blind, randomized, placebo-controlled proof-of-concept study
This study will provide a first proof-of-concept on the potential of the TSPO ligand etifoxine in the treatment of depressive disorders.Trial registrationClinical Trials Register (EudraCT number:2021-006773-38, registration date: 14 September 2022) and German Register of Clinical Studies (DRKS number:DRKS00031099, registration date: 23 January 2023). (Source: Trials)
Source: Trials - April 22, 2024 Category: Research Source Type: clinical trials
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Conditions: Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis Interventions: Drug: Neratinib maleate in combination with capecitabine Sponsors: Convalife (Shanghai) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Task Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based Program
Conditions: Healthy Adults Sponsors: Lumos Labs, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
M3-JIA: Making Mindfulness Matter for Children With JIA
Conditions: Juvenile Idiopathic Arthritis; Children; Mental Health; Mental Well-being Interventions: Behavioral: M3 Intervention group; Behavioral: M3 Waitlist Group Sponsors: Lawson Health Research Institute; Brain Canada Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Pilot and Feasibility of MEMI for Chronic Traumatic Brain Injury
Conditions: Traumatic Brain Injury Interventions: Behavioral: MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval; Behavioral: Blocked Retrieval Sponsors: Vanderbilt University Medical Center Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Digital Sleep Optimization for Brain Health Outcomes in Older Surgical Patients
Conditions: Insomnia; Postoperative Delirium; Delayed Neurocognitive Recovery; Postoperative Neurocognitive Disorder Interventions: Behavioral: digital Cognitive Behavioral Therapy for Insomnia (dCBT-I); Behavioral: Sleep Health Education Sponsors: Massachusetts General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
A Prospective Study of Whole-Brain RT Combined With Thiotepa Sheath Injection Combined With Systemic Therapy for the Primary Disease in the Treatment of Meningeal Metastases in Solid Tumors
Conditions: Solid Tumor Leptomeningeal Metastasis Interventions: Drug: Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Investigating Neurocognitive Disorders Epidemiology
Conditions: Dementia; Cognitive Decline; Alzheimer Disease Interventions: Diagnostic Test: Plasma tau phosphorylated at Thr217; Other: Neurocognitive examination Sponsors: King Chulalongkorn Memorial Hospital; Health Systems Research Institute,Thailand Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
Conditions: Neurocysticercosis Interventions: Drug: albendazole and praziquantel; Drug: Albendazole Sponsors: Dario Scaramuzzi; Muhimbili University of Health and Allied Sciences; National Institute for Medical Research, Tanzania; Sokoine University of Agriculture; University of Zambia; University Ghent Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Genetic Diagnosis in Inborn Errors of Metabolism
Conditions: Metabolic Disease; Mitochondrial Diseases; Epilepsy in Children; Epilepsy; LHON; Motor Neuron Disease Interventions: Genetic: IEM-EP Sponsors: Region Stockholm; Karolinska Institutet Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes
Conditions: Type 2 Diabetes; Microvascular Function; Retinopathy, Diabetic; Nephropathy, Diabetic; Neuropathy, Diabetic Interventions: Dietary Supplement: Pyridoxamine 300mg per day; Other: Placebo 300mg placebo per day Sponsors: Maastricht University Medical Center; Diabetes Fonds Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
The Effect of Tennis Ball on Balance and Quality of Life in Cancer Patients With Neuropathy.
Conditions: Cancer; Neuropathy; Therapy-Associated Cancer Interventions: Other: myofascial release with tennis ball Sponsors: Selcuk University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Personalised Health Cognitive Assistance for RehAbilitation SystEm (PHRASE): A Feasibility Study
Conditions: Stroke Interventions: Device: Rehabilitation Gaming System (VR-based mobile application) Sponsors: Donders Centre for Neuroscience Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON--(BUSINESS WIRE)--Apr. 18, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction
Conditions: Stroke, Acute Ischemic; Blood-Brain Barrier Interventions: Procedure: Y-3 ICO injection; Drug: Y-3 intravenous injection; Other: Conventional treatment Sponsors: yilong Wang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
